JP4615173B2 - ミルクからのオステオポンチンの単離のための方法 - Google Patents
ミルクからのオステオポンチンの単離のための方法 Download PDFInfo
- Publication number
- JP4615173B2 JP4615173B2 JP2001550281A JP2001550281A JP4615173B2 JP 4615173 B2 JP4615173 B2 JP 4615173B2 JP 2001550281 A JP2001550281 A JP 2001550281A JP 2001550281 A JP2001550281 A JP 2001550281A JP 4615173 B2 JP4615173 B2 JP 4615173B2
- Authority
- JP
- Japan
- Prior art keywords
- osteopontin
- milk
- adjusted
- protein
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004264 Osteopontin Human genes 0.000 title claims description 113
- 108010081689 Osteopontin Proteins 0.000 title claims description 113
- 238000000034 method Methods 0.000 title claims description 34
- 235000013336 milk Nutrition 0.000 title claims description 32
- 210000004080 milk Anatomy 0.000 title claims description 32
- 239000008267 milk Substances 0.000 title claims description 32
- 238000002955 isolation Methods 0.000 title description 6
- 239000011575 calcium Substances 0.000 claims description 25
- 108010046377 Whey Proteins Proteins 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 18
- 102000007544 Whey Proteins Human genes 0.000 claims description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- 239000005862 Whey Substances 0.000 claims description 16
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 7
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 238000010909 chemical acidification Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- 102000004169 proteins and genes Human genes 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 239000012528 membrane Substances 0.000 description 31
- 238000001914 filtration Methods 0.000 description 19
- 238000001471 micro-filtration Methods 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000000919 ceramic Substances 0.000 description 12
- 238000011026 diafiltration Methods 0.000 description 12
- 239000012466 permeate Substances 0.000 description 12
- 239000011148 porous material Substances 0.000 description 12
- 108010076119 Caseins Proteins 0.000 description 9
- 102000011632 Caseins Human genes 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000000108 ultra-filtration Methods 0.000 description 9
- 150000001450 anions Chemical class 0.000 description 8
- 239000005018 casein Substances 0.000 description 8
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 8
- 235000021240 caseins Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- -1 tubes Substances 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 238000010979 pH adjustment Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 235000021119 whey protein Nutrition 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000007982 Phosphoproteins Human genes 0.000 description 3
- 108010089430 Phosphoproteins Proteins 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 101000613814 Bos taurus Osteopontin Proteins 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 235000021244 human milk protein Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 108010009004 proteose-peptone Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940006612 barium citrate Drugs 0.000 description 1
- PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011155 wood-plastic composite Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dairy Products (AREA)
- Peptides Or Proteins (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Feed For Specific Animals (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200000013 | 2000-01-07 | ||
| DKPA200000013 | 2000-01-07 | ||
| PCT/DK2001/000005 WO2001049741A2 (fr) | 2000-01-07 | 2001-01-04 | Procede d'isolation d'osteopontine a partir du lait |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003519239A JP2003519239A (ja) | 2003-06-17 |
| JP4615173B2 true JP4615173B2 (ja) | 2011-01-19 |
Family
ID=8158885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001550281A Expired - Lifetime JP4615173B2 (ja) | 2000-01-07 | 2001-01-04 | ミルクからのオステオポンチンの単離のための方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7259243B2 (fr) |
| EP (1) | EP1244702B1 (fr) |
| JP (1) | JP4615173B2 (fr) |
| KR (1) | KR100733538B1 (fr) |
| AR (1) | AR027507A1 (fr) |
| AT (1) | ATE324378T1 (fr) |
| AU (1) | AU784322B2 (fr) |
| CA (1) | CA2396519C (fr) |
| DE (1) | DE60119077T2 (fr) |
| DK (1) | DK1244702T3 (fr) |
| ES (1) | ES2258520T3 (fr) |
| NO (1) | NO330264B1 (fr) |
| NZ (1) | NZ519492A (fr) |
| PT (1) | PT1244702E (fr) |
| RU (1) | RU2264734C2 (fr) |
| WO (1) | WO2001049741A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140029398A (ko) * | 2011-03-03 | 2014-03-10 | 아를라 푸즈 에이엠비에이 | Cmp 또는 카제인 종을 함유하는 원료를 이용한 오스테오폰틴의 단리 방법 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ507335A (en) * | 2000-10-05 | 2004-10-29 | New Zealand Dairy Board | Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP |
| GB0227886D0 (en) * | 2002-11-29 | 2003-01-08 | Medical Res Council | Prion inhibition |
| KR20140073591A (ko) * | 2003-09-18 | 2014-06-16 | 아를라 푸즈 에이엠비에이 | 유아용 조제유 |
| KR101499663B1 (ko) * | 2003-09-18 | 2015-03-06 | 아를라 푸즈 에이엠비에이 | 유아용 조제유 |
| EP1625877A3 (fr) * | 2004-08-09 | 2006-03-08 | Friesland Brands B.V. | Fraction fonctionnelle laitière |
| FR2901796A1 (fr) * | 2006-05-31 | 2007-12-07 | Lab Francais Du Fractionnement | Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait |
| WO2009027284A1 (fr) * | 2007-08-31 | 2009-03-05 | Laboratoires Serono Sa | Purification de l'ostéopontine |
| US9783996B2 (en) | 2007-11-19 | 2017-10-10 | Valinge Innovation Ab | Fibre based panels with a wear resistance surface |
| GB0813015D0 (en) * | 2008-07-16 | 2008-08-20 | Plant Bioscience Ltd | Phosphoproteins and use of the same |
| WO2013086459A1 (fr) | 2011-12-07 | 2013-06-13 | Arla Foods Amba | Variantes d'ostéopontine destinées à être utilisées dans la suppression ou la prévention de la croissance tumorale, et compositions les contenant |
| AU2013241750A1 (en) * | 2012-03-28 | 2014-10-09 | Arla Foods Amba | Nanoparticle aggregates containing osteopontin and calcium- and/or strontium-containing particles |
| AU2014286123B2 (en) | 2013-07-05 | 2019-02-28 | Arla Foods Amba | Mammalian milk osteopontin for enhancing immune responsiveness |
| US12109284B2 (en) | 2016-11-08 | 2024-10-08 | Dentherapy Ltd | Compositions comprising fluoride and calcium and method for preparing them |
| EP3544994B1 (fr) * | 2016-11-27 | 2024-09-25 | Triton Algae Innovations, Inc. | Procédé de purification d'ostéopontine de recombinaison à partir de microalgues |
| GB202010987D0 (en) | 2020-07-16 | 2020-09-02 | Dentherapy Ltd | Oral care compositions and methods |
| CN117377391A (zh) * | 2021-04-19 | 2024-01-09 | 雀巢产品有限公司 | 乳蛋白质级分作为骨桥蛋白源的用途 |
| GB202110114D0 (en) | 2021-07-14 | 2021-08-25 | Dentherapy Ltd | Oral care compositions for use in treaatment |
| WO2023001782A2 (fr) | 2021-07-20 | 2023-01-26 | Arla Foods Amba | Procédé de préparation d'une composition dérivée de lactosérum enrichie en phospholipides et en ostéopontine, composition en tant que telle et utilisation nutritionnelle de la composition |
| WO2024056840A1 (fr) | 2022-09-16 | 2024-03-21 | Univerza V Ljubljani | Isolement de l'ostéopontine et du glycomacropeptide à partir du lactosérum |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0322971A (ja) * | 1989-06-20 | 1991-01-31 | Calpis Food Ind Co Ltd:The | ビフィズス菌増殖物質の精製法及び増殖物質 |
| CH681543A5 (fr) * | 1990-04-27 | 1993-04-15 | Nestle Sa |
-
2001
- 2001-01-04 JP JP2001550281A patent/JP4615173B2/ja not_active Expired - Lifetime
- 2001-01-04 AU AU23528/01A patent/AU784322B2/en not_active Expired
- 2001-01-04 NZ NZ519492A patent/NZ519492A/xx not_active IP Right Cessation
- 2001-01-04 US US10/168,303 patent/US7259243B2/en not_active Expired - Lifetime
- 2001-01-04 DK DK01900100T patent/DK1244702T3/da active
- 2001-01-04 KR KR1020027008782A patent/KR100733538B1/ko active IP Right Grant
- 2001-01-04 EP EP01900100A patent/EP1244702B1/fr not_active Expired - Lifetime
- 2001-01-04 AT AT01900100T patent/ATE324378T1/de active
- 2001-01-04 WO PCT/DK2001/000005 patent/WO2001049741A2/fr active IP Right Grant
- 2001-01-04 CA CA2396519A patent/CA2396519C/fr not_active Expired - Lifetime
- 2001-01-04 ES ES01900100T patent/ES2258520T3/es not_active Expired - Lifetime
- 2001-01-04 DE DE60119077T patent/DE60119077T2/de not_active Expired - Lifetime
- 2001-01-04 RU RU2002118313/13A patent/RU2264734C2/ru active
- 2001-01-04 PT PT01900100T patent/PT1244702E/pt unknown
- 2001-01-05 AR ARP010100042A patent/AR027507A1/es active IP Right Grant
-
2002
- 2002-06-24 NO NO20023057A patent/NO330264B1/no not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140029398A (ko) * | 2011-03-03 | 2014-03-10 | 아를라 푸즈 에이엠비에이 | Cmp 또는 카제인 종을 함유하는 원료를 이용한 오스테오폰틴의 단리 방법 |
| KR101940829B1 (ko) | 2011-03-03 | 2019-01-21 | 아를라 푸즈 에이엠비에이 | Cmp 또는 카제인 종을 함유하는 원료를 이용한 오스테오폰틴의 단리 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001049741A2 (fr) | 2001-07-12 |
| RU2002118313A (ru) | 2004-02-20 |
| US20030149249A1 (en) | 2003-08-07 |
| NO20023057D0 (no) | 2002-06-24 |
| AR027507A1 (es) | 2003-04-02 |
| NZ519492A (en) | 2003-03-28 |
| CA2396519C (fr) | 2011-03-22 |
| NO20023057L (no) | 2002-06-24 |
| ES2258520T3 (es) | 2006-09-01 |
| DE60119077D1 (de) | 2006-06-01 |
| US7259243B2 (en) | 2007-08-21 |
| DE60119077T2 (de) | 2006-09-07 |
| EP1244702B1 (fr) | 2006-04-26 |
| CA2396519A1 (fr) | 2001-07-12 |
| KR100733538B1 (ko) | 2007-06-28 |
| DK1244702T3 (da) | 2006-08-28 |
| NO330264B1 (no) | 2011-03-14 |
| EP1244702A2 (fr) | 2002-10-02 |
| KR20020073159A (ko) | 2002-09-19 |
| JP2003519239A (ja) | 2003-06-17 |
| ATE324378T1 (de) | 2006-05-15 |
| WO2001049741A3 (fr) | 2002-01-17 |
| PT1244702E (pt) | 2006-08-31 |
| RU2264734C2 (ru) | 2005-11-27 |
| AU2352801A (en) | 2001-07-16 |
| AU784322B2 (en) | 2006-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4615173B2 (ja) | ミルクからのオステオポンチンの単離のための方法 | |
| EP0488589B1 (fr) | Procédé de préparation de glycomacropeptides de kappa caseine | |
| US5280107A (en) | Process for producing K-casein glycomacropeptides | |
| JP5967665B2 (ja) | Ｃｍｐまたはカゼイン種を含有する供給物を使用してオステオポンチンを単離する方法 | |
| JPH02276542A (ja) | κ―カゼイングリコマクロペプチドの製造法 | |
| EP0291264B1 (fr) | Procédé de préparation de glycomacropeptide de caséine-K | |
| JPH04225999A (ja) | κ−カゼイノ−グリコマクロペプチドの製造方法 | |
| JP3236828B2 (ja) | 乳カルシウム組成物 | |
| KR20150114968A (ko) | 베타-카제인 조성물의 제조 방법 및 관련 제품들 | |
| EP0580694B1 (fr) | Production de phosphopeptides a partir de la caseine | |
| JP3225080B2 (ja) | κ−カゼイングリコマクロペプチド含有量の高い組成物の製造方法 | |
| EP1037537B1 (fr) | Procede de preparation d'un glycomacropeptide kappa-caseinique ou d'un derive | |
| JP7372232B2 (ja) | κ－カゼイングリコマクロペプチドを含む組成物の製造方法 | |
| JP2745076B2 (ja) | κ―カゼイングリコマクロペプチドの製造法 | |
| JPH05268879A (ja) | α−ラクトアルブミン含有組成物及びその製造方法 | |
| IE920012A1 (en) | Process for the separation of whey proteins and products¹obtained | |
| JP2023149412A (ja) | グリコマクロペプチドおよびαラクトアルブミン含有組成物の製造方法 | |
| KR20230154024A (ko) | 다수의 단백질 공급물을 사용한 베타-락토글로불린의 결정화 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070906 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100615 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100830 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100921 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101020 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4615173 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131029 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |